Mersana Therapeutics (NASDAQ: MRSN) reported Q2 EPS of ($0.20), $0.03 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $2.3 million versus the consensus estimate of $8.72 million.

For earnings history and earnings-related data on Mersana Therapeutics (MRSN) click here.